Literature DB >> 30419091

Errors in Number at Risk and Author Email Address.

.   

Abstract

Year:  2018        PMID： 30419091      PMCID： PMC8177163          DOI： 10.1001/jamaoncol.2018.5345

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  1 in total

1.  Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.

Authors:  Baohui Han; Kai Li; Qiming Wang; Li Zhang; Jianhua Shi; Zhehai Wang; Ying Cheng; Jianxing He; Yuankai Shi; Yizhuo Zhao; Hao Yu; Yang Zhao; Weiqiang Chen; Yi Luo; Lin Wu; Xiuwen Wang; Robert Pirker; Kejun Nan; Faguang Jin; Jian Dong; Baolan Li; Yan Sun
Journal:  JAMA Oncol       Date:  2018-11-01       Impact factor: 31.777
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.